

*The National Academies of*  
SCIENCES • ENGINEERING • MEDICINE

**The State of the Science of Hematopoietic Stem Cell Treatment and Disability: A Workshop**

Monday, November 15, 2021 Eastern Time Zone	
10:00 am	<p><b>Welcome and Workshop Overview</b> Sara Rosenbaum, George Washington University Workshop Planning Committee Chair</p> <p><b>Sponsor Remarks from the Social Security Administration</b> Vincent Nibali, Policy Analyst, Office of Medical Policy, Office of Disability Policy, Social Security Administration Steve Rollins, Deputy Associate Commissioner Office of Disability Policy, Social Security Administration</p>
10:20 am	<p><b>Session 1 -- Hematopoietic Stem Cell Treatment and Disability in the United States</b></p> <p><i>Moderator:</i> Fred Appelbaum, Fred Hutchinson Cancer Research Center</p> <p><b>Understanding Hematopoietic Stem Cell Treatment: Variations, Indications, and Survival</b></p> <ul style="list-style-type: none"> <li>▪ Mary Horowitz, Center for International Blood and Marrow Transplant Research (CIBMTR)</li> </ul> <p><b>Patterns of Recovery in Patients Treated with Hematopoietic Stem Cells</b></p> <ul style="list-style-type: none"> <li>▪ Stephanie Lee, Fred Hutchinson Cancer Research Center; University of Washington</li> </ul> <p><b>Panel Discussion</b></p>
11:25 am	<p><b>Session 2 -- Late Effects of Hematopoietic Stem Cell Treatment</b></p> <p><i>Moderator:</i> Doug Rizzo, Medical College of Wisconsin; CIBMTR</p> <p><b>Immune Recovery in Patients After Hematopoietic Stem Cell Treatment</b></p> <ul style="list-style-type: none"> <li>▪ Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center</li> </ul> <p><b>Graft Versus Host Disease: A Major Complication After Hematopoietic Stem Cell Treatment</b></p> <ul style="list-style-type: none"> <li>▪ Betty K. Hamilton, Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute</li> </ul> <p><b>Considerations in Children and Adolescents Receiving Hematopoietic Stem Cell Treatment and the Transitions into Adulthood</b></p> <ul style="list-style-type: none"> <li>▪ Stella Davies, Cincinnati Children's Hospital Medical Center</li> </ul>



*The National Academies of*  
SCIENCES • ENGINEERING • MEDICINE

	<b>Panel Discussion</b>
<b>12:45 pm</b>	<b>Lunch Break</b>
<b>1:30 pm</b>	<p><b>Session 3 – Hematopoietic Stem Cell Treatment Survivorship</b></p> <p><i>Moderator:</i> Margaret Bevens, National Institutes of Health (NIH)</p> <p><b>Assessing Functional Outcomes in Patients Treated with Hematopoietic Stem Cells</b></p> <ul style="list-style-type: none"> <li>▪ Karen Syrjala, Fred Hutchinson Cancer Research Center</li> </ul> <p><b>Best Practices and Interventions in Hematopoietic Stem Cell Treatment Survivorship</b></p> <ul style="list-style-type: none"> <li>▪ Areej El-Jawahri, Massachusetts General Hospital</li> <li>▪ Staci D. Arnold, Emory University; Children’s Healthcare of Atlanta</li> </ul> <p><b>Patient and Caregiver Experiences</b></p> <ul style="list-style-type: none"> <li>▪ Suzanne McCarroll, patient</li> <li>▪ Margaret Jurocko, caregiver</li> </ul> <p><b>Panel Discussion</b></p>
<b>3:10 pm</b>	<b>Break</b>
<b>3:20 pm</b>	<p><b>Session 4 – The Future Outlook for Stem Cell Treatment and Disability</b></p> <p><i>Moderator:</i> Alexis Thompson, Northwestern University; Ann &amp; Robert H. Lurie Children’s Hospital of Chicago</p> <p><b>Gene Therapy</b></p> <ul style="list-style-type: none"> <li>▪ John Tisdale, National Heart, Lung, and Blood Institute, NIH</li> </ul> <p><b>CAR-T Cell Therapy</b></p> <ul style="list-style-type: none"> <li>▪ David Porter, University of Pennsylvania</li> </ul> <p><b>Preventing/Mitigating Hematopoietic Stem Cell Treatment Complications</b></p> <ul style="list-style-type: none"> <li>▪ Steve Devine, National Marrow Donor Program; CIBMTR</li> </ul> <p><b>Panel Discussion</b></p>
<b>4:25 pm</b>	<p><b>Concluding Remarks</b></p> <p>Sara Rosenbaum, George Washington University Workshop Planning Committee Chair</p>
<b>4:30 pm</b>	<b>Adjourn</b>